Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics Inc (CATX) is a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer treatment. This page provides investors and medical professionals with essential updates on the company’s pioneering work in theranostics, which combines therapeutic isotopes with precision imaging diagnostics.
Access real-time announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection offers transparent insights into the company’s progress with 212Pb-based therapies and their applications across oncology specialties.
Key updates cover FDA submissions, peer-reviewed research findings, and manufacturing advancements. Bookmark this page to monitor how CATX’s proprietary targeting peptides and isotope delivery systems are reshaping radiation oncology.
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) will report its first quarter 2024 financial results on May 15, 2024, showcasing its advancements in radiopharmaceutical treatments for various cancers.
Perspective Therapeutics, Inc. (CATX) has been selected by the FDA to participate in the CDRP program for the development of [212Pb]VMT‐α‐NET for the treatment of patients with NETs. The program aims to expedite the CMC development of novel products under IND applications to provide earlier patient access. The investigational product is intended for PRRT-naïve patients with SSTR2-positive unresectable or metastatic NETs and has been granted Fast Track Designation by the FDA based on preclinical data.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
